After years of training at the highest level, Serena Williams choosing a GLP-1 isn’t taking the “easy” way out—it’s doing what’s best for her body now.

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

GLP-1 drugs may lower the risk of some obesity-related cancers, according to an observational study of people who were overweight or had obesity.

Eli Lilly and Novo Nordisk already make popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site will, too.

Actor Jameela Jamil is calling out the press for inaccurately reporting on what she said about Serena Williams and GLP-1s. Here's what she explained.

About 12% of all U.S. adults have already tried using GLP-1 agonist drugs to control their weight, according to a survey ...

In a recent video spot, the 43-year-old athlete reveals that Ro helped her lose 31 pounds in eight months. “Yes, I’m on Ro.

Celebrities have access to doctors that most others don’t,” Jameela Jamil flags the risks of GLP-1s like those Serena ...

The tennis star has sparked an online debate about whether or not using GLP-1s for weight loss is taking the easy way out.

Tennis star Serena Williams recently attributed her dramatic weight loss to GLP-1 medication but according to “The Good Place ...

A new study led by the Kinsey Institute analyzed how GLP-1 weight-loss drugs are changing people’s dating lives.

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...